In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 303 for your search:
Cancer Type/Condition:  Sezary syndrome
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7273-G000-401, NCT01007448
2.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 78
Sponsor: Pharmaceutical / Industry
Protocol IDs: MOZ11809, NCT01164475
3.

Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572
4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-A23465-21, NCT01569724
5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
6.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958
7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL 2006-1B / ACT-2, BMBF GFVT 01014715, NCT00725231
8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NCI, Other
Protocol IDs: 09-073, NCT00928018
9.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-21081, EU-21020, EUDRACT-2009-011020-65, CELGENE-EORTC-21081, NCT01098656
10.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000702425, EORTC-21082, EU-21116, EUDRACT-2009-011021-13, NCT01386398
12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: 2081-076, NCT01530581
13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25001, 2010-024215-14, NCT01578499
14.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ISS-2007646931, NCT01642563
15.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 82
Sponsor: Other
Protocol IDs: EudraCT 2012-000212-28, 24-169 ex 11/12, NCT01686594
16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
17.

Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0110, NCT00019305
18.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: NHLBI-02-H-0250, NCT00047060
19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 8713-HIMSUM, NCT00058825
20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
21.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: NU 05H8, P30CA060553, NU-0310-101, LILLY-NU-05H8, NCT00369629
22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Other
Protocol IDs: CIK#2/2007, NMRC/1097/2006, NCT00460694
23.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000544786, MAYO-LS0689, MAYO-07-000710, LS0689, NCT00474929
24.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
25.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-001-HMC, NCT00558675
1     
New Search